presence of intron 22 inversion in the patients with severe hemophilia A.

Results Patients were aged 2–30 years. Six (24%) patients were diagnosed during the neonatal period, 11 (44%) between 1–12 months, 5 (20%) between 1–2 years, 2 (8%) between 2–3 years and 1 (4%) at 3.5 years. In our patients, 1–8 joints were affected. The mean joint involvements were 3.3 ± 1.8. Of the 25 patients with severe hemophilia A, 7 patients had the intron 22 inversion. Seven of 15 mothers also presented with the intron 22 inversion. In all 7 cases, mother and son had the same intron 22 inversion, no new mutation was found in our patients.

Conclusion The prevalence of the intron 22 inversion in hemophilic patients is 28%. This prevalence is lower than that reported Worldwide. Based on this study and other reports, we recommended that the detection of intron 22 inversion is performed as a genetic screening test in hemophilic patients.

HUMAN IMMUNOGLOBULINE ROLE IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA

doi:10.1136/archdischild-2012-302724.0749

Introduction Idiopathic thrombocytopenic purpura is a disorder, in which immune system destroys platelets, which are necessary for blood clotting. ITP persons have a very low platelet count. ITP appears when the immune system products antibodies against platelets. This disorder attacks equally boys and girls.

Objective The purpose of study was to present cases and treatment of the patients who are hospitalized in Pediatric Clinic in Prishtina at the hematology-Oncology unit.

Materials and Methods In this study there are included 24 cases that are hospitalized in chemotherapy- Oncology unit during 2011 and their treatment. The diagnose is made based on anamnesis, clinical examinations, laboratory checks, biochemistry, ultrasound examinations, and bone marrow biopsy.

Results 7 cases (29.1%) were treated with human immunoglobulin, while 17 cases (69.9%) were treated with steroids. Immunoglobulin treatment last for 5 days. The second day of treatment with human immunoglobulin the average platelet count increase was 30% higher, while in the fifth day platelet count arrived normal values. In patient treated with steroids platelet count began to rise after one week of treatment., in most cases platelet count was normal after two weeks of treatment.

Conclusion Immunoglobulin therapy is a very efficient therapy in acute idiopathic thrombocytopenia especially in serious and possibly fatal complications such as gastrointestinal and intracranial bleeding.

DETERMINING THE MEAN CORD BLOOD IMMATURE PLATELET FRACTION (IPF) OF HEALTHY NEWBORNs

doi:10.1136/archdischild-2012-302724.0750


Thrombocytopenia is the most common hematologic abnormality in newborn infants Immature platelet fraction (IPF) shows megakaryopoetic activity. The purpose of this study is to provide non-invasive new approach to thrombocytopenic infants for further studies by determining the normal levels of the mean cord blood IPF of healthy newborns.

Methods Healthy newborns who were born at Kocaeli University in 2012, took place in this study. One ml of cord blood was obtained into EDTA tubes. Platelet counts and the mean IPF levels were studied using the point of collection device (XE-100, Sysmex) device. If taking blood to detect blood group is needed in 24–48 hours, IPF levels have been reworked.

Results A total of 75 infants were enrolled in this study. Mean gestational age 37.5, birth weight 3032g, platelet count 234.000/mm3, average levels of cord blood IPF 5.19%, IPF level in 48th hour were found to be 4.3%.

Discussion In healthy adults, the normal values of IPF has been reported as 3.4% on average from 1.1 to 6.1%. Increased levels of IPF are shown to be related to increased platelet production; particularly in disorders related to the destruction of platelets and normal and low values of IPF are shown to be related to decreased platelet production conditions. There are limited number of researches which investigate IPF values in neonates.

Conclusion In this study we found average levels of cord blood is IPF 5.19%. Determining the right approach to thrombocytopenic patients will be possible by recognizing the normal ranges of IPF values in healthy newborns.